-
Ferring announces ground-breaking and inclusive family building benefits package for all its employees globally
in PRESS RELEASE 2022 amFerring Pharmaceuticals is committed to building families of every shape and size. As part of this commitment, Ferring has announced the introduction of a new global family building benefits package for its employees…
-
Ferring Announces New Collaboration for Development of Olamkicept
in PRESS RELEASE 2022 amFerring Pharmaceuticals today announced it has entered into a strategic collaboration with I-Mab to further develop olamkicept in inflammatory bowel disease (IBD) and related inflammatory conditions…
-
Ferring Presents New Analyses of Efficacy, Safety and Microbiome Composition Data at DDW 2022 for RBX2660 its Investigational Microbiota-Based Live Biotherapeutic
in PRESS RELEASE 2022 amNew subgroup analyses presented at Digestive Disease Week® (DDW) 2022 on the integrated efficacy results of Phase 2b and Phase 3 clinical studies of RBX2660.
-
Panicked and overwhelmed: NEW study reveals the emotional and psychological impact of infertility
in PRESS RELEASE 2022 amNew research published in Reproductive Biomedicine, has found that 60% of people believe that the diagnosis and treatment of infertility has impacted their mental health. This impact on mental health has been found to increase with treatment duration and…
-
Gender, health and racial inequalities to be tackled in flagship Ferring grant programme
in PRESS RELEASE 2022 amForensic analysis of stone age human fertility to better understand why modern-day sperm counts are falling, and a project to support safe birth in rural Ethiopia by providing trained midwives and solar power kits, are among 17 winners of a new Ferring Pharmaceuticals…
PRESS RELEASE 2022
PRESS RELEASE 2022
